Recent developments include a $150 million PIPE financing to support the CNS pipeline, mixed Phase 2 trial results for ML-007C-MA in schizophrenia, and ongoing clinical trial readouts anticipated in 2026 and 2027. Insider buying and analyst coverage initiation have also been reported.

• MapLight Therapeutics completed a $150 million private investment in public equity (PIPE) financing to fund its CNS pipeline development efforts [N1].
• The company reported mixed results from the Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia, with the stock declining more than 60% following the announcement [N8].
• ML-007C-MA hit the Phase 2 primary endpoint in schizophrenia, including key cognitive endpoints, despite mixed overall results [N7].
• Topline results for the ZEPHYR Phase 2 trial are anticipated in the third quarter of 2026, with additional Phase 2 readouts anticipated in 2026 and 2027 [N1][S1].
• Insider buying activity was reported in July 2026, indicating confidence from company insiders [N3].
• Analyst coverage was initiated by Canaccord Genuity with a buy recommendation in March 2026 [N2].

MapLight’s lead candidate ML-007C-MA has demonstrated potential in Phase 1 and Phase 2 trials to address unmet needs in schizophrenia and Alzheimer's disease psychosis with a novel mechanism targeting muscarinic receptors. The company’s proprietary platform and intellectual property acquisitions provide a foundation for pipeline expansion. Recent financing activities, including a $150 million PIPE, support continued clinical development. FDA Fast Track designation for ADP may enable expedited regulatory review. Insider buying and analyst coverage initiation indicate market interest and confidence in the company’s prospects.

MapLight faces significant risks typical of clinical-stage biopharmaceutical companies, including the inherent unpredictability of clinical trial outcomes, regulatory approval challenges, and the need for substantial additional funding. Recent Phase 2 ZEPHYR trial results were mixed, with a notable stock price decline following the announcement. The company has no current product revenue and reports ongoing net losses, which may pressure liquidity if financing conditions change. Delays or failures in clinical development or regulatory processes could adversely impact operations and valuation.

MapLight Therapeutics’ moat is based on its proprietary discovery platform that identifies neural circuits causally linked to CNS diseases and targets them for therapeutic modulation. Its lead candidate, ML-007C-MA, combines a muscarinic agonist with a peripherally acting anticholinergic to optimize efficacy and tolerability, supported by clinical and preclinical data. The company’s acquisition of NeuroSolis’s M1/M4 agonist assets and its intellectual property portfolio contribute to its competitive positioning. FDA Fast Track designation for ML-007C-MA in ADP may facilitate regulatory interactions. However, as a clinical-stage company without approved products, its moat depends on successful clinical development and regulatory approval.

• Clinical Development Risk: The success of MapLight’s product candidates depends on the timely and successful completion of clinical trials, which are inherently uncertain and costly. Mixed Phase 2 results highlight this risk.
• Regulatory Approval Risk: Obtaining regulatory approval requires demonstrating safety and efficacy to the satisfaction of authorities such as the FDA. Failure to meet regulatory requirements could delay or prevent commercialization.
• Funding and Liquidity Risk: The company has incurred significant net losses and relies on external financing to fund operations. Inability to raise sufficient capital could force reductions in research and development or operations.
• Operational Risk: As a public company, MapLight faces increased legal, accounting, and compliance costs. Managing growth and clinical programs effectively is critical to execution.

• MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) disorders, including schizophrenia and Alzheimer's disease psychosis (ADP).
• The company was founded by leaders in psychiatry and neuroscience to develop circuit-specific pharmacotherapies targeting neural circuits causally linked to disease.
• Its lead product candidate is ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist co-formulated with a peripherally acting anticholinergic, designed to activate central muscarinic receptors while mitigating peripheral side effects.
• ML-007C-MA is in Phase 2 clinical trials: the ZEPHYR trial for schizophrenia targeting 300 participants with topline results anticipated in Q3 2026, and the VISTA trial for ADP with topline results expected in the second half of 2027.
• ML-007C-MA received FDA Fast Track designation in December 2025 for treatment of hallucinations and delusions associated with ADP.
• The company has conducted four Phase 1 trials with ML-007 and related formulations involving 270 healthy participants and over 1,500 doses administered.
• MapLight has incurred significant net losses since inception, including $161.2 million in 2025 and $77.6 million in 2024, with an accumulated deficit of $360.5 million as of December 31, 2025.
• The company has not generated any revenue to date and does not anticipate product sales revenue in the foreseeable future.
• Operations are financed primarily through sales of redeemable convertible preferred stock, research grants, an IPO in October 2025 raising net proceeds of $261.6 million, and a $150 million PIPE financing in August 2026.
• As of June 30, 2026, MapLight held $71.6 million in cash and equivalents and $233.1 million in short-term investments, with current assets of $318.8 million and current liabilities of $19.3 million, resulting in a current ratio of 16.52 and a cash ratio of 15.79.
• The company reported a net loss of $60.2 million and basic and diluted EPS of -$1.32 for the quarter ended June 30, 2026.
• MapLight leases office and laboratory space in Redwood City, California, and office space in Burlington, Massachusetts, with leases extending through 2029 and 2031.
• The company acquired proprietary M1/M4 agonist molecules and associated intellectual property from NeuroSolis in 2020 and transferred certain technology rights to Stellaromics in 2023 in exchange for equity and continued usage rights.
• Research and development expenses include personnel costs, CRO fees, clinical trial costs, and facility expenses, and are expected to increase as clinical programs advance.
• The company faces risks including the unpredictability of clinical development timelines and costs, regulatory approval challenges, and the need for substantial additional funding to continue operations.
• Recent news highlights include the $150 million PIPE financing to fund the CNS pipeline, mixed Phase 2 ZEPHYR trial results for ML-007C-MA with a stock price decline, and ongoing Phase 2 readouts anticipated in 2026 and 2027.
• Insider buying activity and analyst coverage initiation have been reported, indicating market interest and engagement.
• The company’s common stock began trading on Nasdaq Global Select Market on October 27, 2025, under the ticker MPLT.